Haemonetics Corporation
General ticker "HAE" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $3.0B (TTM average)
Haemonetics Corporation follows the US Stock Market performance with the rate: 31.0%.
Estimated limits based on current volatility of 1.6%: low 101.07$, high 103.96$
Factors to consider:
- Total employees count: 3009 (-0.5%) as of 2026
- US accounted for 74.1% of revenue in the fiscal year ended 2024-03-30
- Top business risk factors: Market competition, Product liability, Regulatory and compliance, Cybersecurity threats, Supply chain disruptions
- Current price 31.8% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-28 to 2028-03-27
- 2026-03-28 to 2027-03-28 estimated range: [49.96$, 78.07$]
- 2027-03-28 to 2028-03-27 estimated range: [54.79$, 83.85$]
Financial Metrics affecting the HAE estimates:
- Negative: with PPE of 11.6 at the end of fiscal year the price was high
- Positive: 7.80 < Operating profit margin, % of 11.75
- Positive: 6.77 < Operating cash flow per share per price, % of 10.81
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 3.90
- Positive: 18.97 < Shareholder equity ratio, % of 33.24 <= 42.26
- Negative: Industry operating profit margin (median), % of -8.30 <= 2.92
- Positive: -14.39 < Investing cash flow per share per price, % of -6.62
- Positive: 0 < Industry operating cash flow per share per price (median), % of 1.58
Short-term HAE quotes
Long-term HAE plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-29 | 2026-03-28 |
|---|---|---|---|
| Operating Revenue | $1,309.06MM | $1,360.82MM | $1,334.03MM |
| Operating Expenses | $1,144.17MM | $1,139.01MM | $1,177.29MM |
| Operating Income | $164.88MM | $221.82MM | $156.73MM |
| Non-Operating Income | $-13.02MM | $-9.75MM | $-28.70MM |
| Interest Expense | $13.02MM | $0.00MM | $0.00MM |
| R&D Expense | $63.03MM | $62.72MM | $59.77MM |
| Income(Loss) | $151.87MM | $212.07MM | $128.03MM |
| Taxes | $34.31MM | $44.39MM | $30.72MM |
| Net Income(Loss)* | $117.56MM | $167.68MM | $97.31MM |
| Stockholders Equity | $959.96MM | $820.84MM | $796.32MM |
| Inventory | $317.20MM | $365.14MM | $306.37MM |
| Assets | $2,195.59MM | $2,450.95MM | $2,395.93MM |
| Operating Cash Flow | $181.75MM | $181.72MM | $293.22MM |
| Capital expenditure | $38.12MM | $39.28MM | $32.78MM |
| Investing Cash Flow | $-322.39MM | $-161.90MM | $-179.55MM |
| Financing Cash Flow | $38.16MM | $108.82MM | $-178.46MM |
| Earnings Per Share** | $2.32 | $3.33 | $2.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.